Clinical and phylogenetic influenza dynamics for the 2019-20 season in the global influenza hospital surveillance network (GIHSN) - Pilot study
Por:
Quéromès G, Frobert E, Burtseva E, Draganescu A, Koul PA, Komissarov A, Laguna-Torres VA, Leblanc J, López-Labrador FX, Medic S, Mironenko A, Otieno NA, Ruiz-Palacios GM, Md T, Ngs Team-Lyon, Gihsn Collaborators, Josset L and Lina B
Publicada:
1 jul 2022
Ahead of Print:
1 may 2022
Resumen:
Background: The Global Influenza Hospital Surveillance Network (GIHSN) has operated with the aim of investigating epidemiological and clinical factors related to severe influenza-related hospitalisations. Study design: A common GIHSN core protocol for prospective patient enrolment was implemented. Hospital personnel completed a standardized questionnaire regarding the included patients' medical history, compiled a hospitalisation summary, collected an upper respiratory swab sample for laboratory diagnosis, and genome sequencing was performed for a subset of samples. Patient data were compared according to influenza subtype, lineage, and phylogenetic groups using the Fisher's exact test. Results: From September 2019 to May 2020, 8791 patients aged >= 5 years were included. Among them, 3021 (34.4%) had a laboratory-confirmed influenza diagnosis. Influenza A(H1N1)pdm09 dominated the season among all age groups, while the B/Victoria-like lineage accounted for over half of the infections among younger age groups (5-49 years). Sequencing of the hemagglutinin segment was possible for 623 samples and revealed an influenza A and B clade frequency among severe influenza hospitalisations similar to other medically attended surveillance networks, such as the WHO GISRS. No phylogenetic clustering was observed among hemagglutinin substitutions depending on the administration of supplemental oxygen or vaccine failure. Conclusions: The GIHSN confirms its ability as an international hospital-based active surveillance network to provide valuable information on influenza infection dynamics in hospital settings. Increasing the number of participating sites and compiling more complete data, such as genome sequencing, will allow the exploration of associations between viral factors, vaccine protection, and disease severity.
Filiaciones:
Quéromès G:
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France
Frobert E:
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France
Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France
Burtseva E:
Ministry of Health of the Russian Federation, FSBI "N.F. Gamaleya NRCEM", Moscow, Russian Federation
Draganescu A:
Matei Bals National Institute for Infectious Diseases, Bucharest, Romania
Koul PA:
Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, Srinagar, India
Komissarov A:
National Influenza Centre, Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation
Laguna-Torres VA:
Tropical Medicine Institute, San Marcos University and Clinica Internacional, Lima, Perú
Leblanc J:
Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH), Halifax, Nova Scotia, Canada
:
Virology Laboratory, Genomics and Health Area, FISABIO - Public Health, Generalitat Valenciana, Valencia, Spain
CIBERESP, Instituto de Salud Carlos III, Madrid, Spain
Medic S:
Department of Epidemiology, Faculty of Medicine, University of Novi Sad, Novi Sad 21000, Serbia
Center for Disease Control and Prevention, Institute of Public Health of Vojvodina, Novi Sad, Serbia
Mironenko A:
Department of Respiratory and other Viral Infections, L.V.Gromashevsky Institute of Epidemiology & Infectious Diseases NAMS of Ukraine, Kyiv, Ukraine
Otieno NA:
Kenya Medical Research Institute - Center for Global Health Research, Kisumu, Kenya
Ruiz-Palacios GM:
Department of Infectious Diseases, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
Md T:
Hacettepe University Faculty of Medicine, Ankara, Turkey
Turkish Society of Internal Medicine, Ankara, Turkey
Ngs Team-Lyon:
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France
Gihsn Collaborators:
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France
Josset L:
CIRI, Centre International de Recherche en Infectiologie, Team VirPatH, Univ Lyon, Inserm, U1111, CNRS, UMR5308, Universit Claude Bernard Lyon 1, ENS de Lyon, Lyon F-69007, France
Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France
Lina B:
Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, Lyon 69317 CEDEX 04, France
Centre National de Référence des virus des infections respiratoires dont la grippe, Lyon, France
hybrid
|